Nasal inflammation, nasal polyps and rhinitis
Drug Safety Update
May 2024: Topical steroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions
August 2017: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration.
December 2014: Inhaled and intranasal corticosteroids.
December 2014: Corticosteroids: early psychiatric side-effects
Important safety information
The CSM recommends that when children are receiving prolonged treatment with nasal corticosteroids the height of the child should be monitored. If growth is slowed than paediatric referral should be considered. They are not licensed for use in young children.
For the general actions, warnings and prescribing notes for steroids, see Corticosteroid responsive conditions
Some brands are available over the counter eg Pirinase Hayfever
| Pack |
|---|
| 150 dose |
| Pack |
|---|
| 120 dose |
| Pack |
|---|
| 30 unit dose (6 x 5 unit doses) |
Licensed in patients over 12 years of age for the treatment of moderate to severe seasonal and perennial allergic rhinitis, if monotherapy with antihistamine or corticosteroid is inadequate
| Pack |
|---|
| 120 dose |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary